Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) EPS (Weighted Average and Diluted) (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed EPS (Weighted Average and Diluted) for 2 consecutive years, with -$0.34 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 2.86% to -$0.34 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.58, a N/A change, with the full-year FY2024 number at -$1.32, up 28.65% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.34 for Q3 2025 at Pyxis Oncology, down from -$0.3 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.06 in Q1 2024 to a low of -$0.59 in Q4 2024.